Kentaro Yamazaki

18PUBLICATIONS
119CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|May 09, 2025
Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study.

Kentaro Sawada, Riu Yamashita, Shunsuke A Sakai

|Apr 10, 2025
Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study.

Takao Fujisawa, Yoshiaki Nakamura, Hideaki Bando

|Mar 25, 2025
A phase 2 study of adjuvant chemotherapy with 5-fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G).

Nozomu Machida, Takehiro Okumura, Narikazu Boku

|Nov 08, 2024
A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan.

Yoshiaki Nakamura, Kristiyana Kaneva, Christine Lo

|Aug 20, 2024
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.

Naoko Iida, Mitsuho Imai, Wataru Okamoto

|Sep 05, 2023
Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm shift in the treatment of resectable gastrointestinal cancer 3)A paradigm shift in the treatment of colorectal cancer.

Kotoe Oshima, Kentaro Yamazaki

Pageof 3

Frequent Collaborators

9 joint publications

Takayuki Yoshino

8 joint publications

Hideaki Bando

7 joint publications

Hiroya Taniguchi

7 joint publications

Eiji Oki